If this phase of the study is only about dosing safety and tolerability then that is where the announcement should start and finish. They mention dosing 13 patients with the agent. They mention 8 interpretable scans. They also mention 2 patients with artefact and 3 patients with tumour invasion and presumably blocked lymphatic drainage. That means 7/13 imaged patients had a useful result. Not 7/8. And if safety and tolerability of the agent was the only point of this phase of the study then why mention the presently limited imaging qualities.
IBX Price at posting:
1.2¢ Sentiment: None Disclosure: Held
